2005
DOI: 10.4161/hv.1.2.1764
|View full text |Cite
|
Sign up to set email alerts
|

Role of Neutralizing Antibodies in Protective Immunity Against HIV

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
28
0
4

Year Published

2007
2007
2022
2022

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 45 publications
(34 citation statements)
references
References 158 publications
2
28
0
4
Order By: Relevance
“…Our preclinical study results also indicated that this combination vaccination approach, but not recombinant protein alone, was effective in eliciting NAbs against primary HIV isolates [19], a finding that has been confirmed subsequently by other independent studies [20][21][22][23][24][25][26]. Furthermore, when polyvalent primary Env antigen formulations were used, the DNA primeprotein boost approach was more effective than the monovalent primary Env antigen in eliciting rabbit NAbs against a wide range of selected primary viral isolates across subtypes A, B, C, D and E [27].…”
Section: Introductionsupporting
confidence: 80%
“…Our preclinical study results also indicated that this combination vaccination approach, but not recombinant protein alone, was effective in eliciting NAbs against primary HIV isolates [19], a finding that has been confirmed subsequently by other independent studies [20][21][22][23][24][25][26]. Furthermore, when polyvalent primary Env antigen formulations were used, the DNA primeprotein boost approach was more effective than the monovalent primary Env antigen in eliciting rabbit NAbs against a wide range of selected primary viral isolates across subtypes A, B, C, D and E [27].…”
Section: Introductionsupporting
confidence: 80%
“…The difficulty in eliciting a broad and potent neutralizing antibody response against HIV-1 is thought to reside in the high degree of genetic diversity of the virus, in the heterogeneity of Env on the surface of HIV-1, and in the masking of functional regions by conformational covering, by an extensive glycan shield, or by the ability of some conserved domains to partition to the viral membrane (24,25,29,30,38,39,56,68,69). So far, vaccine trials using as immunogens mimics of Env in different conformations have primarily elicited antibodies with only limited neutralization potency across different HIV-1 clades although recent work has demonstrated more encouraging results (4,12,61).…”
mentioning
confidence: 99%
“…However, several observations indicate that, although cell-mediated immunity is crucial for controlling and eradicating viral infections, neutralizing antibodies are pivotal in reducing the infectivity titer of the initial HIV-1 inoculum (potentially to sterilization) as well as neutralizing free virions during the first rounds of replication. This greatly facilitates the outcome of the second line of defense operated by effector T cells that are required to eliminate virus-infected cells [19][20][21][22]. Consequently, anti-HIV-1 prime-boost vaccination strategies should include a protein component to induce an optimal titer of neutralizing antibodies [23;24].…”
Section: Introductionmentioning
confidence: 99%